Join our newsletter
Get updated info, tips and news about breastfeeding, e-lactancia project and other initiatives from APILAM
Legitimation: Consent of the interested party
As a user and interested I inform you that the data you provide will be located on the servers of MailChimp (email marketing provider of APILAM) outside the EU in the USA. MailChimp is covered by the EU-US Privacy Shield agreement, whose information is available here, approved by the European Committee for Data Protection. See Mailchimp's privacy policy. (https://mailchimp.com/legal/privacy/).
The fact that you do not enter the personal data that appear on the form as mandatory may have the consequence that we can not meet your request.
You can exercise your rights of access, rectification, limitation and delete the data in apilam.es@gmail.com as well as the right to file a claim with a control authority.
You can consult the additional and detailed information on Data Protection on this website: http://e-lactancia.org, as well as consult our own privacy policy.
Intermediate-acting Benzodiazepine. indicated in certain forms of epilepsy and in panic disorder with or without agoraphobia.
Oral or intravenous administration 3 times a day.
It is excreted in milk in very small quantities (Nishimura 2021, Schaefer 2007 p701, Misri 2006, Söderman 1988, Fisher 1985).
The plasma levels of infants whose mothers took a dose of 0.25 to 4 mg per day were undetectable or very low, less than 15 micrograms/L (Birnbaum 1999, Söderman 1988, Fisher 1985).
Higher levels (20-22 micrograms/L) were found in two cases; in one of them the mother took a 6 mg daily dose of clonazepam (Schaefer 2007 p701, Birnbaum 1999).
No side effects were found in infants whose mothers were taking clonazepam (Nishimura 2021, Misri 2006, Birnbaum 1999), unless they were taking more than one medication with neurological effects (Kelly 2012, Schaefer 2007 p701) or if the mother was already taking clonazepam during pregnancy and associated with prematurity (Fisher 1985).
The frequency of reported side effects is very low: a single case demonstrated in 26 and a half years of follow-up in the French Pharmacovigilance Database (Soussan 2014).
Whether anxiolytic rather than anticonvulsivant treatment is intended, benzodiazepines with a shorter half-life span like Lorazepam or Oxazepam should be considered.
The occasional use and low doses of benzodiazepines are compatible with breastfeeding (Kelly 2012, Rubin 2004, Iqbal 2002, Hägg 2000, McElhatton 1994, Lee 1993, Kanto 1982).
Several medical societies, experts and expert consensus, consider the use of clonazepam safe during breastfeeding (Briggs 2017, Picchietti 2015, WHO2002), especially at doses no greater than 1 mg per day (Picchietti 2015).
It is advisable to choose a short-acting benzodiazepine and minimal effective dose as possible (Rowe 2013), especially in the neonatal period and in case of prematurity because they can accumulate in the infant during chronic use (Sachs 2013, Amir 2011).
It is advisable to monitor drowsiness and adequate feeding of the infant (LactMed rev.2018, Crettenand 2018).
It is not recommended to share a bed (co-sleeping, bed-sharing) with the baby if this drug is being taken, due to increased risk of asphyxia or sudden infant death (UNICEF UK 2018, 2017, 2014 and 2013, Landa 2012, ABM 2008, UNICEF UK 2006).